***Amendments to the Claims***

This listing of claims will replace all prior versions, and listings of claims in the application.

Claims 1-16 (cancelled).

17. (currently amended) Vaccine containing one or more synthetic or purified natural peptides or proteins as antigen(s) as well as one or more adjuvants, characterised in that it is present as a solution or emulsion which is substantially free from inorganic salt ions, wherein said solution or emulsion contains one or more water soluble or water-emulsifiable substances which is capable of making the vaccine isotonic or hypotonic, said substance(s) selected from the group consisting of:

a) a maltose;

b) a fructose;

c) a galactose;

d) a saccharose;

e) a sugar alcohol;

g) a lipid; and

h) combinations thereof[.],

<u>wherein at least one of said adjuvants is a polycation, optionally modified with a sugar group.</u>

Claims 18-24 (cancelled).

25. (previously presented) Vaccine according to claim 17, characterized in that said water soluble or water-emulsifiable substance is present in a concentration such that the resulting solution is isotonic.

Claims 26-29 (cancelled).

30. (previously presented) Vaccine according to claim 17, characterized in that it additionally contains a buffer.

31. (previously presented) Vaccine according to claim 17, characterized in that it contains a peptide as the antigen.

32. (currently amended) Vaccine according to claim 31, characterized in that the peptide is [derived from] a tumour antigen or a fragment thereof and is capable of binding to MHC molecules.

33. (cancelled)

34. (previously presented) Vaccine according to claim 17, characterized in that it contains polyarginine as the adjuvant.

35. (previously presented) Vaccine according to claim 17, characterized in that said water soluble or water-emulsifiable substance is present in a concentration such that the resulting solution is hypotonic.

36. (previously presented) The vaccine formulation of claim 17, wherein said water soluble or water-emulsifiable substance is a sugar alcohol.

37. (previously presented) The vaccine formulation of claim 17, wherein said water soluble or water-emulsifiable substance is maltose.

38. (previously presented) The vaccine formulation of claim 17, wherein said water soluble or water-emulsifiable substance is fructose.

39. (previously presented) The vaccine formulation of claim 17, wherein said water soluble or water-emulsifiable substance is galactose.

40. (previously presented) The vaccine formulation of claim 17, wherein said water soluble or water-emulsifiable substance is saccharose.

41 (previously presented) Vaccine according to claim 36, characterized in that the sugar alcohol is mannitol.

42. (previously presented) The vaccine formulation of claim 17, wherein said water soluble or water-emulsifiable substance is a lipid.

43. (previously presented) The vaccine formulation of claim 17, wherein said said water soluble or water-emulsifiable substances are selected from the group consisting of maltose, fructose, galactose, saccharose and combinations thereof.

44. (previously presented) The vaccine formulation of claim 43, characterized in that the concentration of the water soluble or water-emulsifiable substances is in the range from about 200-400 mM.

45. (previously presented) The vaccine formulation of claim 44, characterized in that the concentration of the water soluble or water-emulsifiable substances is in the range from about 250-300 mM.

46. (previously presented) The vaccine formulation of claim 17, characterized in that the concentration of the water soluble or water-emulsifiable substances is in the range from about 200-400 mM.

47. (previously presented) The vaccine formulation of claim 46, characterized in that the concentration of the water soluble or water-emulsifiable substances is in the range from about 250-300 mM.

48. (new) The vaccine according to claim 36, wherein said sugar alcohol is sorbitol.

49. (new) The vaccine according to claim 36, characterized in that the concentration of sugar alcohol is in the range from about 200-400 mM.

50. (new) The vaccine according to claim 48, characterized in that the concentration of sorbitol is 250-300 mM.

51. (new) The vaccine according to claim 17, wherein said vaccine is in solution form.

52. (new) The vaccine according to claim 17, wherein said vaccine is in emulsion form.

53. (new) The vaccine according to claim 51, wherein said adjuvant is selected from the group consisting of polyarginine and polylysine.

54. (new) The vaccine according to claim 53, wherein said adjuvant is polylysine.

55. (new) The vaccine according to claim 54, wherein said isotonic making substance is a sugar alcohol.

56. (new) The vaccine according to claim 55, wherein said sugar alcohol is sorbitol.